Sandoz Zarxio Launch Still Faces Hurdles; ‘Chess Game’ With Amgen Continues
Executive Summary
Federal Circuit ruling frees Sandoz to begin marketing first U.S. biosimilar after Sept. 2 but it still must overcome pending infringement suit and chance Amgen will assert more patents.
You may also be interested in...
Biosimilar Sponsors Are Not Liable Under State Law For Declining Patent Dance
US Federal Circuit finds in Amgen v. Sandoz that the BPCIA preempts innovator companies from seeking penalties under state law against a biosimilar sponsor that does not engage in the 'patent dance.'
Biosimilar Sponsors Are Not Liable Under State Law For Declining Patent Dance
US Federal Circuit finds in Amgen v. Sandoz that the BPCIA preempts innovator companies from seeking penalties under state law against a biosimilar sponsor that does not engage in the 'patent dance.'
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.